Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432

2013/12/11 by Harry P. Erba, Megan Othus, Roland B. Walter +9 · 2 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Acute Myeloid Leukemia Research #Multiple Myeloma Research and Treatments #Retinoids in leukemia and cellular processes

paper · doi:10.1016/j.leukres.2013.12.001

openalex publication_date 2013/12/11 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Cited by

• A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia
• Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial